There is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.
Show figures in :Show figures in :
Data is unavailable
Data is unavailable
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | |
|---|---|---|---|---|---|---|---|
| Net worth | 1696.58 | 2050.67 | 1735.18 | 1527.18 | 1180.81 | 844.76 | 590.29 |
| Fixed assets | 1713.42 | 669.62 | 663.33 | 534.19 | 441.16 | 356.74 | 270.90 |
| Debt | 78.13 | 38.58 | 69.16 | 95.57 | 141.23 | 185.29 | 82.79 |
View detailed balance sheet
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|
| Operating | 288.16 | 384.77 | 457.20 | 330.00 | 382.55 | 406.92 | 50.40 |
| Investing | -255.30 | -362.35 | -195.01 | -136.14 | -311.40 | -413.45 | -65.48 |
| Financing | 3.32 | -39.99 | -241.95 | -156.48 | -75.66 | 7.32 | 25.98 |
Cohance is a global, technology‑driven CDMO offering end‑to‑end development and manufacturing solutions across Pharma CDMO, Specialty Chemicals and API+ verticals.
Cohance serves customers in 25 countries, with exports accounting for 90.64% of turnover in the latest year.
Cohance acquired stakes in NJ Bio and Sapala Organics to expand capabilities in ADCs and oligonucleotides and changed its name to Cohance Lifesciences Limited. The Company also restated prior standalone figures following the merger of Casper Pharma Private Limited, effective January 1, 2025.
